Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Phase 2

Completed

Conditions: Ulcerative Colitis
Crohn's Disease

Interventions: Drug: Vedolizumab

First Posted Date: 2017-05-03

Last Posted Date: 2020-12-21

Lead Sponsor: Takeda

Target Recruit Count: 89

Registration Number: NCT03138655

Locations: 🇺🇸
Children's Center for Digestive Healthcare, Atlanta, Georgia, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
University Hospitals Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States

and more 85 locations

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: 30 mg dexlansoprazole capsules manufactured at TOB
Drug: 60 mg dexlansoprazole capsules manufactured at TOB
Drug: 30 mg dexlansoprazole capsules manufactured at TPC
Drug: 60 mg dexlansoprazole capsules manufactured at TPC

First Posted Date: 2017-04-27

Last Posted Date: 2019-06-14

Lead Sponsor: Takeda

Target Recruit Count: 116

Registration Number: NCT03131895

Locations: 🇺🇸
PRAHS Phase 1 unit, Salt Lake City, Utah, United States

Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation

Phase 4

Completed

Conditions: Reflux Esophagitis

Interventions: Drug: Vonoprazan

First Posted Date: 2017-04-17

Last Posted Date: 2019-03-29

Lead Sponsor: Takeda

Target Recruit Count: 3

Registration Number: NCT03116841

Locations: 🇯🇵
Tokatsu Tsujinaka Hospital, Abiko, Chiba, Japan
🇯🇵
Aoyama Clinic, Kobe, Hyogo, Japan
🇯🇵
Saino Clinic, Tokorozawa, Saitama, Japan

and more 3 locations

IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults

Phase 1

Terminated

Conditions: Poliomyelitis

Interventions: Biological: Reference IPV
Biological: sIPV Placebo
Biological: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)

First Posted Date: 2017-03-28

Last Posted Date: 2020-01-31

Lead Sponsor: Takeda

Target Recruit Count: 340

Registration Number: NCT03092791

Locations: 🇵🇦
CEVAXIN - David, Chiriqui, Panama
🇵🇦
CEVAXIN Plaza Carolina - Ciudad de Panama, Ciudad de Panama, Panama
🇵🇦
CEVAXIN - 24 de Diciembre, Panama, Panama

and more 1 locations

Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets

Completed

Conditions: Crohn Disease
Colitis, Ulcerative
Inflammatory Bowel Diseases

Interventions: Drug: Anti-TNF Therapy

First Posted Date: 2017-03-24

Last Posted Date: 2018-06-26

Lead Sponsor: Takeda

Target Recruit Count: 1731

Registration Number: NCT03090139

Locations: 🇦🇷
Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina
🇦🇷
Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

and more 73 locations

A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: TAK-438

First Posted Date: 2017-03-21

Last Posted Date: 2019-01-30

Lead Sponsor: Takeda

Target Recruit Count: 33

Registration Number: NCT03085836

Locations: 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, China

A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Capsule and Tablet Formulation in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Esomeprazole Capsule
Drug: Esomeprazole Tablet

First Posted Date: 2017-03-20

Last Posted Date: 2019-06-14

Lead Sponsor: Takeda

Target Recruit Count: 52

Registration Number: NCT03083639

Locations: 🇺🇸
Pharmaceutical Research Associates, Inc., Lenexa, Kansas, United States

Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable Technology

Completed

Conditions: Major Depressive Disorder

Interventions: Other: No intervention

First Posted Date: 2017-03-01

Last Posted Date: 2019-01-10

Lead Sponsor: Takeda

Target Recruit Count: 30

Registration Number: NCT03067506

Locations: 🇬🇧
Takeda Investigative Site, London, United Kingdom

Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection

Phase 3

Completed

Conditions: Gastric Ulcer

Interventions: Drug: TAK-438
Drug: Lansoprazole
Drug: Lansoprazole Placebo
Drug: TAK-438 Placebo
Drug: Bismuth-Containing Quadruple Therapy

First Posted Date: 2017-02-10

Last Posted Date: 2021-06-18

Lead Sponsor: Takeda

Target Recruit Count: 234

Registration Number: NCT03050307

Locations: 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
Yijishan hospital of Wan nan Medical college, Wuhu, Anhui, China
🇨🇳
Beijing Chao Yang Hospital, Beijing, Beijing, China

and more 78 locations

Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection

Phase 3

Completed

Conditions: Duodenal Ulcer

Interventions: Drug: TAK-438
Drug: Lansoprazole
Drug: Lansoprazole Placebo
Drug: TAK-438 Placebo
Drug: Bismuth-Containing Quadruple Therapy

First Posted Date: 2017-02-10

Last Posted Date: 2020-06-12

Lead Sponsor: Takeda

Target Recruit Count: 533

Registration Number: NCT03050359

Locations: 🇨🇳
Shiyan Taihe Hospital, Shiyan, Hebei, China
🇨🇳
Jiangxi Nanchang 3rd Hospital, Nanchang, Jiangxi, China
🇰🇷
Korea University Ansan Hospital, Ansan-si, Gyeonggi-do, Korea, Republic of

and more 78 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy